Comorbidity in Adult Psoriasis: Considerations for the Clinician

Daugaard, Christine; Iversen, Lars; Hjuler, Kasper Fjellhaugen

doi:10.2147/ptt.s328572

Cited by 18 publications

(11 citation statements)

References 163 publications

(144 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is commonly associated with mental disorders, especially depression and anxiety [ 7 ]. Psoriasis is a lifelong relapsing-remitting illness that negatively impacts people's quality of life (QoL).…”

Section: Reviewmentioning

confidence: 99%

“…The global burden of disease study found that 5.6 million persons of all age groups had disability-adjusted life years (DALYs) related to psoriasis in 2016 [ 4 ]. Another term for psoriasis is "systemic disease having multiple comorbidities,” i.e., cardiovascular disease (CVD), psoriatic arthritis (PSA), and mental disorders [ 7 ]. Psoriasis is the most common chronic skin disorder, negatively affecting psychological interactions and health.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

Hepat¹,

Chakole²,

Rannaware³

2023

Cureus

View full text Add to dashboard Cite

Psoriasis is a chronic systemic inflammatory condition, and psychiatric comorbidities are common in this condition. It is a non-communicable, autoimmune, and incurable disease. Psoriasis causes an adverse effect and is connected with various psychological symptoms like social isolation, guilt, and embarrassment of a patient. They decrease self-esteem because of depression, anxiety, stress, and substance abuse adults. The prevalence rate of adults is gradually increasing. This study uses various scales to evaluate the level of psoriasis. This study aims to evaluate the level of depression, anxiety, stress, and substance abuse among adult psoriasis patients and to identify the factors affecting psoriasis patients. A detailed search was carried out using essential databases such as PubMed, Google Scholar, and the World Health Organization (WHO) database to search for articles elucidating the same. In total articles, 36 out of 160 are selected. All studies found that psoriasis is at a positive level in that the level of depression and anxiety is moderate to severe, the level of stress is moderate, the level of alcohol abuse is higher, and the level of smoking consumption is ever-increasing. A severe skin condition that impacts the quality of life and psychological health. It has become a public health issue. All the selected articles assessed patients who were highly affected by depression, anxiety, stress, and abuse. They also assessed the various comorbidities related to psoriasis.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

Hepat¹,

Chakole²,

Rannaware³

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The clinical characteristics of psoriasis include silvery scales, red plaques, and skin thickening. Psoriasis has been associated with several comorbidities, including cardiovascular disorders, depression, social isolation, and all-cause mortality (Daugaard et al, 2022). Patients with psoriasis also have an increased risk of melanoma and non-melanoma skin cancers (Coates et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

The anti‐inflammatory activity of flavonoids and alkaloids from Sophora flavescens alleviates psoriasiform lesions: Prenylation and methoxylation beneficially enhance bioactivity and skin targeting

Lin,

Hung

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

The herb Sophora flavescens displays anti‐inflammatory activity and can provide a source of antipsoriatic medications. We aimed to evaluate whether S. flavescens extracts and compounds can relieve psoriasiform inflammation. The ability of flavonoids (maackiain, sophoraflavanone G, leachianone A) and alkaloids (matrine, oxymatrine) isolated from S. flavescens to inhibit production of cytokine/chemokines was examined in keratinocytes and macrophages. Physicochemical properties and skin absorption were determined by in silico molecular modeling and the in vitro permeation test (IVPT) to establish the structure‐permeation relationship (SPR). The ethyl acetate extract exhibited higher inhibition of interleukin (IL)‐6, IL‐8, and CXCL1 production in tumor necrosis factor‐α‐stimulated keratinocytes compared to the ethanol and water extracts. The flavonoids demonstrated higher cytokine/chemokine inhibition than alkaloids, with the prenylated flavanones (sophoraflavanone G, leachianone A) led to the highest suppression. Flavonoids exerted anti‐inflammatory effects via the extracellular signal‐regulated kinase, p38, activator protein‐1, and nuclear factor‐κB signaling pathways. In the IVPT, prenylation of the flavanone skeleton significantly promoted skin absorption from 0.01 to 0.22 nmol/mg (sophoraflavanone G vs. eriodictyol). Further methoxylation of a prenylated flavanone (leachianone A) elevated skin absorption to 2.65 nmol/mg. Topical leachianone A reduced the epidermal thickness in IMQ‐treated mice by 47%, and inhibited cutaneous scaling and cytokine/chemokine overexpression at comparable levels to a commercial betamethasone product. Thus, prenylation and methoxylation of S. flavescens flavanones may enable the design of novel antipsoriatic agents.

show abstract

“…Psoriasis may cause social stigmatization and degrade the patients’ quality of life 3 , 4 . Recently, multiple studies have reported that psoriasis 1 is associated with not only previously well-known comorbidities—such as psoriatic arthritis, Crohn's disease, and uveitis—but also other chronic diseases, including cardiovascular disease, hypertension, diabetes, hyperlipidemia, and even psychiatric comorbidities 5 – 7 . Therefore, psoriasis is considered a systemic disease with a fairly high burden.…”

Section: Introductionmentioning

confidence: 99%

Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program

Jung,

Kim,

Cho

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Biologics for psoriasis are efficient and safe, but very expensive. We investigated the association of the reducing copayment program (RCP) with changes in biologics use patterns depending on the income levels of patients with moderate-to-severe psoriasis. This nationwide cohort study included patients identified as having moderate-to-severe psoriasis between 2014 and 2020. Logistic regression models were used to estimate the odds ratio for the use of biologics according to income levels. Among 57,139 patients with moderate-to-severe psoriasis, 3464 (6.1%) used biologics for psoriasis from 2014 to 2020. After the introduction of RCP in 2017, the proportion of patients with moderate-to-severe psoriasis using biologics rapidly increased from 5.0% in 2016 to 19.2% in 2020; the increase was more remarkable in patients with the lowest or mid-low income compared to those with Medical Aid. Drug survival of biologics was higher in patients with the highest income before the RCP, but became comparable between those with high and low incomes after RCP introduction. The introduction of RCP was associated with an increased use of biologics in patients with moderate-to-severe psoriasis of all income levels; however, the effect was more pronounced in low-income patients. The RCP may contribute to alleviating the disparity in access to biologics.

show abstract

Comorbidity in Adult Psoriasis: Considerations for the Clinician

Cited by 18 publications

References 163 publications

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

The anti‐inflammatory activity of flavonoids and alkaloids from Sophora flavescens alleviates psoriasiform lesions: Prenylation and methoxylation beneficially enhance bioactivity and skin targeting

Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program

Contact Info

Product

Resources

About